The dual-incretin molecule, read at the chemistry: how one engineered 39-residue peptide moves blood pressure, lipids and weight in the trial record.
Tirzepatide Chemical

What Is Tirzepatide? The Dual GIP/GLP-1 Peptide Explained — Tirzepatide Chemical

The short version

What is tirzepatide? It is a once-weekly injectable medication, approved by the FDA in 2022, that works by mimicking two gut hormones at once — GIP and GLP-1 — to lower blood sugar, reduce body weight, lower blood pressure, and improve cholesterol. Most medications in its class only target GLP-1; tirzepatide hits both, which is why its trial results are consistently larger. It is given as a subcutaneous (under-the-skin) injection once a week, starting at a low dose and stepping up over several months. It is a prescription drug — not available over the counter — and it does not work the same way as older diabetes medications like insulin or metformin. It is a peptide: a short protein chain, not a traditional small-molecule drug. The chemistry and the trial numbers behind what it does are what this page covers.

What is tirzepatide? The dual GIP/GLP-1 peptide explained

Tirzepatide (INN: tirzepatide; developmental code: LY3298176) is a synthetic incretin-mimetic peptide — a drug engineered to behave like the gut hormones GIP and GLP-1 at their respective receptors, simultaneously. The molecule is a 39-amino-acid linear chain built on the native GIP hormone backbone, with a C20 eicosanedioic-acid fatty-diacid arm attached via a glutamic acid linker and two AEEA (2-(2-aminoethoxy)ethoxy)acetic acid) units to a lysine side chain. That fatty-diacid arm binds serum albumin — the most abundant protein in blood — and dramatically extends the molecule's residence time, achieving an elimination half-life of approximately five days. One injection lasts a week [1].

The discovery paper (Coskun et al., 2018) reported that tirzepatide activated both GIP and GLP-1 receptor signalling in vitro; that chronic administration to mice reduced body weight and food intake more than a selective GLP-1 receptor agonist; and that a 142-subject Phase 1 human programme supported once-weekly dosing and showed reduced fasting glucose and body weight versus placebo [1].

A follow-up mechanistic study (Willard et al., 2020) characterised tirzepatide as an imbalanced, biased dual agonist: it engages the GIP receptor more fully than the GLP-1 receptor, and at the GLP-1 receptor it preferentially drives cAMP signalling over beta-arrestin recruitment — a profile proposed to enhance insulin secretion while reducing desensitisation [2].

The StatPearls clinical reference confirms: tirzepatide is an FDA-approved dual agonist of the GLP-1 and GIP receptors, approved in May 2022 for type 2 diabetes mellitus [7].

Tirzepatide peptide: structure and identifiers

Tirzepatide is classified as a synthetic incretin-mimetic peptide — not a small molecule and not a biological drug derived from a living organism.

  • Molecular formula: C225H348N48O68
  • Molecular weight: 4,813.53 Da
  • CAS number: 2023788-19-2
  • ATC code: A10BX16
  • Drug class: dual GIP and GLP-1 receptor agonist ("twincretin" or "dual incretin mimetic")
  • Half-life: ~5 days
  • Route: subcutaneous injection (the only route in the approved and clinical-trial programmes)
  • Dosing: once weekly; titrated from 2.5 mg starting dose up to a maximum 15 mg over approximately five months

The incretin hormones it mimics — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) — are released from the gut after eating and amplify glucose-dependent insulin secretion. Tirzepatide is not endogenous: it is an engineered peptide, though modelled on the native GIP backbone [1].

What is tirzepatide used for? FDA-approved indications

The FDA has approved tirzepatide for three indications:

  1. Type 2 diabetes mellitus (May 2022): as an adjunct to diet and exercise to improve glycaemic control in adults
  2. Chronic weight management (November 2023): for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition
  3. Moderate-to-severe obstructive sleep apnea in adults with obesity

The StatPearls chapter notes that weight-loss use in adults without diabetes was an off-label indication prior to the November 2023 approval, and that the agent is not approved for type 1 diabetes [7].

Beyond these indications, the clinical programme includes SYNERGY-NASH/SYNERGY-MASH (metabolic dysfunction-associated steatohepatitis with liver fibrosis), SUMMIT (heart failure with preserved ejection fraction and obesity), and SURPASS-CVOT (cardiovascular outcomes in type 2 diabetes with established cardiovascular disease) [9][12][15].

How does tirzepatide work?

By engaging both the GIP and GLP-1 receptors, tirzepatide triggers several metabolic effects simultaneously:

  • Glucose-dependent insulin secretion: both receptors amplify insulin release — but only when blood glucose is elevated, so the risk of low blood sugar on its own is low
  • Glucagon suppression: GLP-1 receptor activation suppresses glucagon (the hormone that raises blood glucose), reducing hepatic glucose output after meals
  • Gastric emptying delay: slowing gastric emptying extends the feeling of fullness and blunts post-meal glucose spikes
  • Appetite suppression: GLP-1 receptor activation in the central nervous system reduces appetite and food intake

The combination of these four effects — more than any single effect alone — is what produces the cardiometabolic readouts in the trial record: the HbA1c reductions, the body-weight reductions, and the blood-pressure and lipid improvements [1][2].

For the full mechanism discussion, including the imbalanced-biased-agonism profile, see Tirzepatide research.

How long does tirzepatide stay in your system?

Tirzepatide has an elimination half-life of approximately five days, consistent with the albumin-binding fatty-diacid modification and the once-weekly clinical-trial and approved dosing schedule. A single dose therefore takes roughly 25-35 days to be fully eliminated (five to seven half-lives). The clinical-trial pharmacokinetic characterisation (Urva et al., 2020) documented the PK profile supporting once-weekly dosing [1]. The five-day half-life is the longest elimination half-life in the approved incretin class and is the structural innovation — the C20-eicosanedioic-acid arm — that makes it possible.